Psoriasis rates rise globally, with highest burden in wealthier regions
Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to continue rising for both men and women through 2050.
MeSH tree: C17.800.859
Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to continue rising for both men and women through 2050.
Chronic pruritus is prevalent among older adults and is associated with moderately impaired pruritus-specific quality of life, according to a study published online Nov. 10 in Acta Dermato Venereologica.
Nov 25, 2025
0
11
Researchers at the Perelman School of Medicine at the University of Pennsylvania report that adults with seborrheic dermatitis in a large US cohort had higher odds of multiple epithelial barrier diseases across skin, respiratory, ...
New research has updated the understanding of how sugars, known as glycans, help immune cells move into the skin in the inflammatory disease, psoriasis.
Nov 4, 2025
1
2372
Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to treatment. EULAR—The European Alliance of Associations for Rheumatology—has released new evidence-based ...
Oct 30, 2025
0
18
Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern suggesting" a lower five-year risk of any first cancer (excluding non-melanoma skin cancer) with ustekinumab ...
A mutation previously linked to skin disorders like psoriasis may also play a surprising role in gut health, according to new research published by scientists at VIB-UGent and colleagues from UGent, the University of Barcelona, ...
Oct 23, 2025
0
23
New longitudinal research reveals that severe stress caused by changes in family structure like divorce or separation experienced during the first year of life may triple the risk of developing psoriasis later in life.
Oct 21, 2025
0
11
A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in an international clinical trial of more than 200 patients worldwide.
Oct 7, 2025
0
73
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.
Oct 3, 2025
0
17